Physician profile
Manuel Rodriguez
NPI 1972500254
$263,304.92
in general payments reported to CMS, 2019-2025
69 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,481 · 2020: $30K · 2021: $58K · 2022: $51K · 2023: $11K · 2024: $17K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Food and Beverage: $14K · Travel and Lodging: $11K · Consulting Fee: $6,025 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,989.94 |
| Food and Beverage | $13,764.72 |
| Travel and Lodging | $11,052.27 |
| Consulting Fee | $6,025.00 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $150,703.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $50,935.11 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $18,182.35 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13,439.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $5,833.97 | 2025 | Caplyta |
| Pfizer INC. | $5,215.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,367.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,803.51 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $2,234.05 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $2,003.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,099.02 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $953.39 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $951.69 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $574.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $574.13 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.